Guanhua Lu

Guanhua Lu

Auto-generated profile, based on publicly available information

Guanhua Lu

Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
GLGuanhua Lu
Guanhua Lu
HGHuanhuan Gao
Huanhuan Gao
ZDZhiyong Dong
Zhiyong Dong
SJShuwen Jiang
Shuwen Jiang
RHRuixiang Hu
Ruixiang Hu
CWCunchuan Wang
Cunchuan Wang
Background: MicroRNAs (miRNAs) exert an essential contribution to obesity and type 2 diabetes mellitus (T2DM). This study aimed to investigate the differences of miRNAs in the presence and absence of T2DM in patients with obesity, as well as before and after bariatric surgery in T2DM patients with obesity. Characterization of the common changes in both was further analyzed.Methods: We enrolled 15 patients with obesity but without T2DM and 15 patients with both obesity and T2DM. Their preoperative clinical data and serum samples were collected, as well as 1 month after bariatric surgery. The serum samples were analyzed by miRNA sequencing, and the miRNAs profiles and target genes characteristics were compared.Results: Patients with T2DM had 16 up-regulated and 32 down-regulated miRNAs compared to patients without T2DM. Improvement in metabolic metrics after bariatric surgery of T2DM patients with obesity was correlated with changes in miRNAs, as evidenced by the upregulation of 20 miRNAs and the downregulation of 30 miRNAs. Analysis of the two miRNAs profiles identified seven intersecting miRNAs that showed opposite changes. The target genes of these seven miRNAs were substantially enriched in terms or pathways associated with T2DM.Conclusion: We determined the expression profiles of miRNAs in the obese population, with and without diabetes, before and after bariatric surgery. The miRNAs that intersected in the two comparisons were discovered. Both the miRNAs discovered and their target genes were closely associated with T2DM, demonstrating that they might be potential targets for the regulation of T2DM.

15 March 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
YYYi Yang
Yi Yang
XWXiaoli Wang
Xiaoli Wang
JLJin Lu
Jin Lu
ZDZhiyong Dong
Zhiyong Dong
RHRuixiang Hu
Ruixiang Hu
CWCunchuan Wang
Cunchuan Wang
Colorectal cancer (CRC) is a common and highly lethal gastrointestinal malignancy. Immunotherapy has shown positive efficacy in the treatment of CRC; however, only a minority of patients benefit from immunotherapy. The aim of this study is to construct a cuproptosis-related lncRNA (CRLs) risk score model to predict the prognosis and immune infiltration of CRC patients. Firstly, we synthetically analyzed 19 cuproptosis-related genes (CRGs) from CRC samples derived from the TCGA and obtained 33 CRLs that were significantly associated with prognosis. Next, we defined three cuproptosis modification patterns via consensus clustering analysis (C1, C2, and C3). Further analysis showed that there were significant differences in the abundance of B cells, NK cells, fibroblasts, monocytes, CD8+ cells, bone marrow dendritic cells, and cytotoxic lymphocytes in different clusters. In addition, the LASSO regression screened out 6 individual CRLs (AC009315.1, PLS3-AS1, ZEB1-AS1, AC007608.3, AC010789.2, and AC010207.1) closely related to the prognosis of CRC. We found that the low-risk group had better survival prognoses in patients. Furthermore, the high-risk group had lower immune scores and exhibited lower CD8+ T cell infiltration. Moreover, the low-risk group had lower immune exclusion, immune dysfunction and TIDE scores than the high-risk group. Interestingly, the lncRNAs in our risk model were positively associated with most immune checkpoints. CD274 (PD-L1), CTLA4, and HAVCR2 (TIM3) were positively correlated with risk scores. Moreover, MSI-H patients had lower risk scores than MSI-L patients, and IPS scores were significantly higher in the low CRLs score group. In conclusion, we constructed a novel risk score model with6 lncRNAs related to cuproptosis, which may be a potential biomarker for evaluating the prognosis and immune treatment for CRC.

6 October 2025 in International Journal of Surgery
Verified
Journal Article
Open access
FLFenmei Liang
Fenmei Liang
GLGuanhua Lu
Guanhua Lu
DSDexun Sun
Dexun Sun
PCPangzhou Chen
Pangzhou Chen
YSYichuan Shi
Yichuan Shi
XCXinxin Chen
Xinxin Chen
Background: Taxane-associated acute pain syndrome (T-APS) is a frequent adverse effect in breast cancer patients undergoing nab-paclitaxel, affecting treatment adherence and quality of life (QoL). We analyzed the effectiveness of preventative celecoxib on T-APS among these patients. Methods: This non-randomized controlled trial included 270 breast cancer patients receiving nab-paclitaxel who experienced musculoskeletal pain during the first cycle. Subjects were assigned to receive celecoxib (200 mg, administered on Days 1–7) or a placebo. The main outcome measured was the overall incidence of severe T-APS (>5 on a 0–10 scale) during cycles 2–4. Secondary endpoints included the incidence, severity, and duration of T-APS (assessed by the Brief Pain Inventory scale); QoL; peripheral nerve function; and adverse events. Results: The overall incidence of severe T-APS was 10.2% in the celecoxib group and 50.0% in the placebo group during cycles 2–4 ( P < 0.001). Mean FACT-B subscale scores were significantly higher in the celecoxib group (101.62, 95% CI: 99.70–103.53; 105.59, 95% CI: 103.57–107.61; and 108.02, 95%CI: 106.18–109.85) than the placebo group (99.02, 95% CI: 97.29–100.76; 99.80, 95% CI: 98.03–101.57; and 99.10, 95% CI: 97.39–100.81) ( P < 0.05). QoL on EORTC QLQ-C30 was also better in the celecoxib group, except for appetite loss, fatigue, and insomnia ( P < 0.05). Following four cycles, the mean scores on the FACT-Ntx subscale in the celecoxib group remained higher (34.10, 95% CI: 33.29–34.91 vs 32.25, 95% CI: 31.63–32.88) ( P < 0.01). Additionally, the incidence of peripheral neuropathy at grade 1 or higher in CTCAE 5.0 was reduced in the celecoxib group (36.7% vs 63.8%, P < 0.001). Conclusion: Preventative celecoxib significantly reduced the incidence of severe T-APS and improved QoL in breast cancer patients.

19 August 2024 in Cancer Medicine
Verified
Journal Article
Open access
DSDexun Sun
Dexun Sun
GLGuanhua Lu
Guanhua Lu
FLFenmei Liang
Fenmei Liang
WZWangjian Zhang
Wangjian Zhang
TZTao Zeng
Tao Zeng
XCXinxin Chen
Xinxin Chen
Objective: This study aimed to verify if intraoperative radiotherapy (IORT) can achieve the same survival outcome as whole‐breast external beam radiotherapy (EBRT) in early breast cancer after breast‐conserving surgery (BCS), and to explore the suitable candidates that can safely receive IORT after BCS.Methods: Eligible post‐BCS patients who received IORT or EBRT were included in the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2018. Risk factors that affected 5‐year overall survival (OS) or breast cancer specific survival (BCSS) were identified by Cox proportional hazards regression analysis. Clinical characteristics, OS, and BCSS were comparatively analyzed between the two treatment modalities.Results: The survival analysis after propensity score matching confirmed that patients who received IORT (n = 2200) had a better 5‐year OS than those who received EBRT (n = 2200) (p = 0.015). However, the two groups did not differ significantly in 5‐year BCSS (p = 0.381). This feature persisted even after multivariate analyses that took into account numerous clinical characteristics. Although there was no significant difference in BCSS between different subgroups of patients treated with IORT or EBRT, patients over 55 years of age, with T1, N0, non‐triple negative breast cancers, hormone receptor‐positive, and histologic grade II showed a better OS after receiving IORT.Conclusion: In low‐risk, early‐stage breast cancer, IORT was not inferior to EBRT considering 5‐year BCSS and OS. Considering the equivalent clinical outcome but less radiotoxicity, IORT might be a reasonable alternative to EBRT in highly selective patients undergoing BCS.